Phase 2 data for OCS-01, a proprietary topical nanoparticle formulation of dexamethasone from Oculis to treat patients with diabetic macular edema, demonstrated clinical proof of concept as a topical drug and greater efficacy than vehicle in reducing central macular thickness and improving visual acuity.
Pravin U. Dugel, MD, presented positive data for OCS-01 at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2020 symposium in Miami. Patients were randomly assigned to receive one drop of either OCS-01 or a matching vehicle eye drop three times per day for 12
Uncategorized